

JNITED STATES D

s department of commerce

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/423,516 02/10/00 GHERARDI E 1090-26 **EXAMINER** HM22/0913 <u>HAVES</u> NIXON & VANDERHYE PAPER NUMBER ART UNIT 1100 NORTH GLEBE ROAD 8TH FLOOR ARLINGTON VA 22201-4714 1647 DATE MAILED: 09/13/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No. Applicant(s)		
Office Action Summary	09/423516	Gherard	i et al.
	Examiner	Art Uni	
	Robert Haye	164	7
The MAILING DATE of this communication appears	on the cover sheet wi	ith the corresponde	enc address
Period for Reply	Δ.		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SE THE MAILING DATE OF THIS COMMUNICATION.	T TO EXPIRE	MONTH(S)	FROM
 Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a rep be considered timely. If NO period for reply is specified above, the maximum statutory period communication. Failure to reply within the set or extended period for reply will, by statute. Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). 	oly within the statutory mining will apply and will expire St.	num of thirty (30) days X (6) MONTHS from to secome ABANDONED	will he mailing date of this (35 U.S.C. § 133).
Status	,		
1) 図 Responsive to communication(s) filed on	101		
2a) ☐ This action is FINAL . 2b) ☑ This acti			
3) Since this application is in condition for allowance exclosed in accordance with the practice under Ex pa			o the merits is
Disposition of Claims			
4) 区 Claim(s) 1~3O	·	is	/are pending in the applica
4a) Of the above, claim(s)		is/a	re withdrawn from considera
5)			is/are allowed.
6)			is/are rejected.
7)			is/are objected to
8) 🔀 Claims 1 - 30	a	re subject to restri	ction and/or election requirem
Application Papers	a.		
9) The specification is objected to by the Examiner.			
10) The drawing(s) filed on is/a	re objected to by the E	Examiner.	
11) The proposed drawing correction filed on	is: aʃ☐	approved b)⊡di	sapproved.
12) \square The oath or declaration is objected to by the Examine	} Γ.		
Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign prio a) All b) Some* c) None of:	rity under 35 U.S.C. §	119(a)-(d).	
1. Certified copies of the priority documents have	heen received		
2. Certified copies of the priority documents have		ication No	
3. Copies of the certified copies of the priority doc			
application from the International Bureau *See the attached detailed Office action for a list of the	(PCT Rule 17.2(a)).		la Glage
14) Acknowledgement is made of a claim for domestic pr			
Attachment(s)			
15) Notice of References Cited (PTO-892)	18) Interview Summary (P	TO-413) Paper No(s).	
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Pate		
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Cther:		

140

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 2, 5-21 and 24-37 (each in part) and claims 3 and 22 (each in full), drawn to variant HGF with reduced sulphate binding but still capable of binding its cognate receptor, wherein at least amino acid R73 has been replaced with an amino acid with no charge or negative charge, as well as polynucleotides encoding same, vectors and host cells comprising the polynucleotide, methods of recombinantly expressing the polypeptide and methods of treatment comprising administering the HGF to the patient.

Group II, claim(s) 1, 2, 5-21 and 24-37 (each in part) and claims 4 and 23 (each in full), drawn to variant HGF with reduced sulphate binding but still capable of binding its cognate receptor, wherein at least amino acid R76 has been replaced with an amino acid with no charge or negative charge, as well as polynucleotides encoding same, vectors and host cells comprising the polynucleotide, methods of recombinantly expressing the polypeptide and methods of treatment comprising administering the HGF to the patient..

Application/Control Number: 09/423,516

Art Unit: 1646

The inventions listed as Groups I and II do not relate to a single general inventive concept

under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special

technical features for the following reasons: the specific technical feature of invention I is an HGF

with a modification at amino acid 73. The modified HGF of invention II does not require this

modification, but instead requires a modification at amino acid 76. The two modified HGF's are

structurally distinct, requiring non-coextensive searches of the art, including database searches.

Invention I defines a contribution over the art which is distinct from that of Invention II. Therefore,

there is a lack of unity of invention.

Applicant is advised that the reply to this requirement to be complete must include an election

of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee

required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Robert Hayes, Ph.D., whose telephone number is (703) 305-3132.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Gary Kunz, Ph.D., can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal

communications with the examiner should be directed to (703) 308-0294.

ECK

September 12, 2001

Elyabetz C. Kemmen

ELIZABETH KEMMERER PRIMARY EXAMINER

Page 3